Lifecycle of a medical device in the UK

Regulatory basis

This page provides a lifecycle overview across the UK Medical Devices Regulations 2002 (SI 2002/618, as amended). Each stage links to dedicated pages with full regulatory detail.

Disclaimer

This site provides general information only and does not constitute legal or regulatory advice. Always consult the official legislation text and MHRA guidance before making regulatory decisions.

The regulatory lifecycle at a glance

The regulatory lifecycle of a medical device in the UK does not begin when a device is placed on the market — it begins in the design phase, and it continues until the last device is removed from service. MHRA's oversight spans the entire lifecycle, and manufacturers bear obligations at every stage.

CONCEPT & DESIGN
      │
      ▼
CLASSIFICATION
(determine Class I / IIa / IIb / III / AIMD / IVD category)
      │
      ▼
ESSENTIAL REQUIREMENTS
(demonstrate conformity with Schedule 1 / Schedule 1A)
      │
      ▼
TECHNICAL FILE / DESIGN DOSSIER
(compile evidence of conformity)
      │
      ▼
CLINICAL / PERFORMANCE EVALUATION
(clinical evidence appropriate to class)
      │
      ▼
CONFORMITY ASSESSMENT
(self-declaration for Class I/General IVD — UKAB for all others)
      │
      ▼
UK DECLARATION OF CONFORMITY + UKCA MARK
(or CE mark under transitional acceptance)
      │
      ▼
MHRA REGISTRATION
(via MHRA Submissions portal — mandatory before placing on GB market)
      │
      ▼
PLACING ON THE MARKET / PUTTING INTO SERVICE
      │
      ▼
POST-MARKET SURVEILLANCE
(active monitoring of real-world performance)
      │
      ▼
VIGILANCE REPORTING
(serious incidents and FSCAs to MHRA within statutory timeframes)
      │
      ▼
PERIODIC SAFETY UPDATE REPORTS
(PSURs — for Class IIa, IIb, III, AIMD where applicable)
      │
      ▼
CHANGES & VARIATIONS
(technical file updates; UKAB notification where required)
      │
      ▼
RECALL / FIELD SAFETY CORRECTIVE ACTION
(where safety issues identified)
      │
      ▼
END OF MARKET AVAILABILITY / DECOMMISSIONING

Stage 1: Concept and design

Regulatory thinking should begin before detailed design work, not after. Early regulatory considerations include:

Intended purpose: defining precisely what the device is for — the foundation of all subsequent regulatory decisions
User population: who will use the device and in what setting
Technology type: is it active, implantable, invasive, an IVD, software?
Regulatory strategy: which markets? GB only, GB + EU, global?
Predecessor devices and predicate analysis: are there equivalent devices already on the market?
Applicable standards: which ISO/EN/BS standards are relevant (ISO 13485, ISO 14971, IEC 60601 series, etc.)?

A Quality Management System (QMS) conforming to ISO 13485 should be in place before clinical or performance evaluation activities begin. MHRA expects manufacturers to operate a QMS throughout the lifecycle.

Stage 2: Classification

Classification determines everything that follows. Manufacturers must apply the classification rules in Schedule 2 of UK MDR 2002 (for general devices) or the Annex II lists of Part III (for IVDs).

Class / Category	Risk level	UKAB needed?
Class I	Lowest	No (except sterile, measuring, reusable surgical instruments — partial UKAB)
Class IIa	Low-medium	Yes
Class IIb	Medium-high	Yes
Class III	Highest	Yes — full assessment
AIMD	Highest (single tier)	Yes — full assessment
IVD General	Lowest	No
IVD Self-test	Variable	Yes
IVD List B	Significant	Yes
IVD List A	Highest	Yes — full assessment

Classification must be documented in the technical file with a rationale referencing the specific Schedule 2 rules applied.

See How classification works for the full rule-by-rule detail.

Stage 3: Essential Requirements

All devices — regardless of class — must demonstrate conformity with the Essential Requirements set out in:

Schedule 1, UK MDR 2002 — for general devices and AIMDs
Schedule 1A, UK MDR 2002 — for IVDs

The Essential Requirements cover:

General safety and performance principles
Design and construction requirements specific to the device type
Requirements for devices with a measuring function
Requirements for devices placed on the market in a sterile condition
Information to be supplied with the device (labelling and IFU)

Conformity with designated UK standards (harmonised standards adopted by BSI) provides a presumption of conformity with the relevant Essential Requirements. See Essential Requirements.

Stage 4: Technical file

The technical file is the core document demonstrating that the device meets the Essential Requirements. It must include:

General description of the device and its intended purpose
Design specifications, drawings, and manufacturing information
Classification rationale
Essential Requirements checklist with evidence of conformity
Risk management documentation (ISO 14971 risk management file)
Clinical evaluation report (or performance evaluation report for IVDs)
Pre-clinical testing results (biocompatibility, sterilisation validation, electrical safety, EMC, etc.)
Labelling and IFU
Post-market surveillance plan

For Class III and AIMD devices, a more detailed design dossier is required and must be submitted to a UKAB for examination.

The technical file must be maintained and updated throughout the device's market life. See Technical documentation.

Stage 5: Clinical and performance evaluation

Manufacturers must provide clinical evidence appropriate to their device's classification and intended purpose:

General medical devices: Clinical Evaluation Report (CER) based on clinical data from literature, equivalent devices, and/or clinical investigations
IVDs: Performance Evaluation Report (PER) covering analytical and clinical performance

Clinical evaluation is not a one-time activity — it must be updated as part of post-market clinical follow-up (PMCF) throughout the device's market life.

See Clinical evidence.

Stage 6: Conformity assessment

The conformity assessment procedure confirms that the device meets the Essential Requirements. The procedure depends on device class:

Device class	Conformity assessment route
Class I (standard)	Manufacturer self-declaration
Class I (sterile / measuring / reusable surgical)	Self-declaration + UKAB for specific aspects
Class IIa	UKAB: QMS assessment (Annex II-equivalent) or type-examination
Class IIb	UKAB: full QMS assessment
Class III / AIMD	UKAB: full QMS + design dossier examination
IVD General	Manufacturer self-declaration
IVD Self-test	UKAB involvement
IVD List B	UKAB: type-examination
IVD List A	UKAB: design dossier + production quality assurance

The conformity assessment culminates in the manufacturer issuing a UK Declaration of Conformity and affixing the UKCA mark (or relying on CE marking under transitional acceptance until 30 June 2030).

See Conformity assessment.

Stage 7: MHRA registration

Before placing any device on the GB market, the manufacturer (or their UKRP) must register with MHRA via the MHRA Submissions portal.

Registration covers:

The manufacturer's legal entity
The UKRP (for non-UK manufacturers)
Device descriptions, classification, and certificate references

Registration is a mandatory administrative step — separate from, and in addition to, the conformity assessment process.

See MHRA registration.

Stage 8: Placing on the market

A device is "placed on the market" when it is first made available on the GB market — i.e., supplied to a distributor, retailer, or user. At this point:

The device must bear the UKCA mark (or CE mark under transitional acceptance)
The Declaration of Conformity must exist and be accessible
MHRA registration must be complete
Labelling and IFU must comply with UK MDR 2002 requirements

"Putting into service" — the first use of a device for its intended purpose — may occur later (e.g., for capital equipment).

Stage 9: Post-market surveillance (PMS)

Once on the market, the manufacturer must actively monitor the device's real-world performance. PMS is not passive — it requires a documented plan and systematic collection and analysis of post-market data.

PMS data sources include:

Complaint records
Adverse event reports from users
Published literature on equivalent devices
Registries and post-market clinical follow-up (PMCF) studies
Sales and distribution records

PMS feeds back into the risk management file, clinical evaluation, and technical documentation — which must all be kept current.

See Post-market surveillance.

Stage 10: Vigilance reporting

When a device causes — or may cause — a serious injury or death, or a malfunction that could cause or contribute to a serious injury, the manufacturer must report to MHRA within statutory timeframes:

Event type	Reporting timeframe
Serious public health threat	Immediately — no later than 2 calendar days
Death or unanticipated serious deterioration of health	No later than 10 calendar days
Other reportable serious incident	No later than 30 calendar days
Trend reporting (increased frequency of non-serious incidents)	No later than 30 calendar days after trend identified

Reports are submitted to MHRA via the Yellow Card scheme or MHRA Submissions portal.

See Vigilance & adverse event reporting.

Stage 11: Periodic Safety Update Reports (PSURs)

For Class IIa, IIb, III, and AIMD devices, manufacturers must produce Periodic Safety Update Reports (PSURs) that summarise the conclusions of post-market surveillance data analysis and confirm the device's benefit-risk profile remains acceptable.

PSUR frequency:

Class IIa: At least every 2 years
Class IIb and III, AIMD: At least annually

PSURs must be made available to UKABs and MHRA on request.

See Post-market surveillance.

Stage 12: Changes and variations

Any significant change to the device — design, materials, manufacturing process, intended purpose, labelling — must be assessed for its impact on conformity with the Essential Requirements.

Significant changes may require:

Technical file update
UKAB notification or re-assessment (for certified devices)
New Declaration of Conformity
MHRA registration update

Manufacturers should have a documented change control procedure within their QMS.

See Keeping registration up to date.

Stage 13: Field Safety Corrective Actions (FSCAs) and recalls

When a safety issue is identified in the field — whether through vigilance reporting, PMS, MHRA notification, or any other source — the manufacturer must assess whether a Field Safety Corrective Action (FSCA) is required.

An FSCA may involve:

Recall of devices from users or market
Device modification or retrofit
Change in labelling or IFU
Restriction of use
Advice to healthcare professionals (via Field Safety Notice)

All FSCAs and Field Safety Notices (FSNs) must be reported to MHRA.

See Field Safety Corrective Actions.

Stage 14: End of market availability

When a device is withdrawn from the market, certain obligations continue:

Traceability records must be retained (minimum 5 years general, 10 years for implantable devices)
Technical documentation must remain accessible
PMS and vigilance obligations continue for devices already in service
MHRA registration should be updated to reflect the withdrawal

MHRA may require manufacturers to maintain support (spare parts, maintenance) for implantable devices already implanted in patients even after market withdrawal.

Official references

Reference	Description
UK MDR 2002 (SI 2002/618)	Full regulatory framework
MHRA: Regulating medical devices in the UK	Lifecycle overview guidance
ISO 13485:2016	QMS for medical devices — lifecycle requirements
ISO 14971:2019	Risk management — applies throughout lifecycle
MHRA: Adverse incident reporting	Vigilance reporting requirements

The regulatory lifecycle at a glance​

Stage 1: Concept and design​

Stage 2: Classification​

Stage 3: Essential Requirements​

Stage 4: Technical file​

Stage 5: Clinical and performance evaluation​

Stage 6: Conformity assessment​

Stage 7: MHRA registration​

Stage 8: Placing on the market​

Stage 9: Post-market surveillance (PMS)​

Stage 10: Vigilance reporting​

Stage 11: Periodic Safety Update Reports (PSURs)​

Stage 12: Changes and variations​

Stage 13: Field Safety Corrective Actions (FSCAs) and recalls​

Stage 14: End of market availability​

Related pages​

Official references​